DV
Dividend Vision

CRMD — CorMedix Inc

CorMedix Inc (CRMD)

Total return is -49.7% over the past 16.3 years, 842.9 points behind SPY at 793.2%. Its deepest 1-year drawdown was 57.9%.

CorMedix Inc. is a biopharmaceutical company developing and commercializing therapeutic products for life-threatening diseases, with its lead product candidate being DefenCath, an antimicrobial catheter lock solution designed to reduce catheter-related bloodstream infections in adult kidney failure patients. The company does not currently distribute dividends. CorMedix appeals to investors seeking exposure to early-stage biotech development with a focus on infectious disease prevention in clinical settings.

CRMD key facts

Asset type
Stock
Asset class
Equity
Inception date
05/13/2010
Last close
$7.54
Market cap
$660,564,928
Average volume
2698500.0
Payment date
03/26/2019
Beta
1.481
Payout ratio
0.0
P/E ratio
3.8802
Forward P/E
16.5017
EPS
$2.17